Linagliptine Zentiva

Linagliptin, the active ingredient in Linagliptine Zentiva, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. This includes regulatory compliance and temperature‑controlled shipping where required.

Linagliptine Zentiva, a DPP‑4 inhibitor, is used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus (monotherapy): improves glycaemic control as a single oral agent. - Type 2 diabetes mellitus (add‑on to metformin): enhances glucose control when combined with metformin. - Type 2 diabetes mellitus (combination therapy): used with other oral antidiabetics to achieve target HbA1c.

Linagliptine Zentiva may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Nasopharyngitis - Upper respiratory tract infection - Dizziness

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (anaphylaxis) - Bullous pemphigoid

Before prescribing Linagliptine Zentiva, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: monitor renal function regularly, although dose adjustment is not required. - Hepatic impairment: use with caution and assess liver enzymes. - History of pancreatitis: avoid use or monitor closely for abdominal pain. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia, adjust co‑medication as needed. - Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies the risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linagliptine Zentiva can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other DPP‑4 inhibitors (e.g., saxagliptin): may increase risk of adverse effects. - Combination with insulin or sulfonylureas: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptine plasma concentrations. - Diuretics: potential for dehydration, monitor fluid status. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may lower drug exposure.